Trial Profile
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 22 Mar 2023 Planned End Date changed from 23 Oct 2022 to 23 Oct 2028.
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 01 Mar 2022 Planned End Date changed from 4 Feb 2022 to 23 Oct 2022.